Impact of immune-related adverse event severity on overall survival in patients with advanced NSCLC receiving immune checkpoint inhibitors therapy, with a focus on combination regimens

Lung, Respiratory and Thoracic Cancer

Factors Associated with Disease Progression after Discontinuation of Immune Checkpoint Inhibitors for Immune-Related Toxicity in Patients with Advanced Non-Small Cell Lung Cancer

Clin Cancer Res

Pecci F, Thummalapalli R, Alden SL, Ricciuti B, Alessi JV, Elkrief A, Rizvi H, Wang X, Jeng M, Egger JV, Vaz VR, Barrichello A, Lamberti G, Di Federico A, Santo V, Rossato de Almeida G, Gandhi M, Clark P, Nishino M, Johnson BE, Hellmann M, Schoenfeld AJ, Awad MM

doi: 10.1158/1078-0432.CCR-24-2990

Lung, Respiratory and Thoracic Cancer

Pretreatment eosinophilia as a biomarker for adverse outcomes in non-small cell lung cancer patients receiving immune checkpoint inhibitors: A systematic review and meta-analysis

Semin Oncol

Ganatra N, Thompson J, Desai R, Doshi J, Jain P, Pasnoor DS, Jain A

doi: 10.1016/j.seminoncol.2025.152431

Further Publications

Impact of edoxaban-related adverse events in patients with cancer experiencing venous thromboembolism during antineoplastic therapy: Results of the phase IV EDOI study (GOIRC-05-2018)

Eur J Cancer

Maglietta G, Damato A, Finotto S, Mandarà M, Tamberi S, Grisanti S, Brighenti M, Tiseo M, Montesarchio V, Catino A, Gelsomino F, Giovanardi F, Antonuzzo L, Romagnani A, Gervasi E, Di Maio M, Pinto C

doi: 10.1016/j.ejca.2025.115296

Further Publications

The association between metformin use, immune mediated colitis and overall survival in patients treated with checkpoint inhibitor

Eur J Cancer

Shatila M, Cruz CC, Lu L, Abdul-Baki K, Baerman E, Takigawa K, Rivera AU, Lee IJ, Ngo S, Sperling G, Aleem AS, Menon R, Sullivan A, Vemulapalli V, Natha C, Gupta T, Khan A, Mittal N, Coleman G, Salim H, Wali S, Varatharajalu K, Kim KC, Reddy SA, Grivas P, Thomas AS, Wang Y

doi: 10.1016/j.ejca.2025.115405

Lung, Respiratory and Thoracic Cancer

Immune checkpoint inhibitor-induced interstitial lung disease with and without CTLA-4 regimen in non-small cell lung cancer patients and PD-L1

Lung Cancer

Murata D, Azuma K, Murotani K, Ito K, Nomizo T, Yamada K, Imabayashi T, Iwanaga K, Chibana K, Ota T, Nishii Y, Nakao A, Okada A, Hamai K, Tanimura K, Yoshimine K, Tamura Y, Takaki R, Goto Y, Hibino M, Oba T, Sumi T, Kaneda H, Nishioka N, Yamada T, Takayama K

doi: 10.1016/j.lungcan.2025.108772

RECOMMENDED

Lung, Respiratory and Thoracic Cancer

Real-world survival outcomes of immune checkpoint inhibitor therapy after standard treatment failure in EGFR-mutated NSCLC: A nationwide cohort study

★ 1 Recommended by Dr Martin Frey, Faculty Member

★ 1 Recommended by Dr Marcus Hesse, Faculty Member

Lung Cancer

Lee J, Kim M, Han HJ, Kim S, Suh HS

doi: 10.1016/j.lungcan.2025.108682

SPECIAL REPORT

Lung, Respiratory and Thoracic Cancer

COCOON Study: Enhanced dermatologic management reduces dermatologic adverse events with amivantamab plus lazertinib in patients with NSCLC harboring common EGFR mutations*

Further Publications

Outcomes of Solid Organ Transplant Recipients With Advanced Cancers Receiving Immune Checkpoint Inhibitors: A Systematic Review and Individual Participant Data Meta-Analysis

JAMA Oncol

Saleem N, Wang J, Rejuso A, Teixeira-Pinto A, Stephens JH, Wilson A, Kieu A, Gately RP, Boroumand F, Chung E, Bonevski B, Carlino MS, Carroll R, Lim WH, Craig JC, Murakami N, Wong G

doi: 10.1001/jamaoncol.2025.2374

Lung, Respiratory and Thoracic CancerCOVID-19

Prognostic impact of HNF4α expression in TTF-1-negative non-squamous NSCLC treated with immune checkpoint inhibitor

Lung Cancer

Iso H, Ariyasu R, Fujishima S, Ito M, Nibuya K, Sugai M, Tsugitomi R, Amino Y, Uchibori K, Yanagitani N, Ninomiya H, Seike M, Nishio M

doi: 10.1016/j.lungcan.2025.108631

Related content

Factors Associated with Disease Progression after Discontinuation of Immune Checkpoint Inhibitors for Immune-Related Toxicity in Patients with Advanced Non-Small Cell Lung Cancer

Pretreatment eosinophilia as a biomarker for adverse outcomes in non-small cell lung cancer patients receiving immune checkpoint inhibitors: A systematic review and meta-analysis

Impact of edoxaban-related adverse events in patients with cancer experiencing venous thromboembolism during antineoplastic therapy: Results of the phase IV EDOI study (GOIRC-05-2018)

The association between metformin use, immune mediated colitis and overall survival in patients treated with checkpoint inhibitor

Immune checkpoint inhibitor-induced interstitial lung disease with and without CTLA-4 regimen in non-small cell lung cancer patients and PD-L1

Real-world survival outcomes of immune checkpoint inhibitor therapy after standard treatment failure in EGFR-mutated NSCLC: A nationwide cohort study

COCOON Study: Enhanced dermatologic management reduces dermatologic adverse events with amivantamab plus lazertinib in patients with NSCLC harboring common EGFR mutations*

Outcomes of Solid Organ Transplant Recipients With Advanced Cancers Receiving Immune Checkpoint Inhibitors: A Systematic Review and Individual Participant Data Meta-Analysis

Prognostic impact of HNF4α expression in TTF-1-negative non-squamous NSCLC treated with immune checkpoint inhibitor